Achieve Life Sciences, Inc. Common Shares ACHV
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T09:40:13.281Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T22:19:59.157876208Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T09:40:12.603057+00:00
Achieve Life Sciences, Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 5.34 | 281.2% | 32.8% | |||
| 30Δ | 5.88 | 286.1% | 29.7% | |||
| 35Δ | 6.42 | 291.0% | 26.5% | |||
| 40Δ | 6.96 | 295.9% | 23.4% | |||
| 45Δ | 7.49 | 300.7% | 20.2% | |||
| 50Δ | 6.51 | 168.4% | 14.2% | 7.80 | 283.1% | 18.0% |
| 55Δ | 6.24 | 187.9% | 13.5% | 8.11 | 265.2% | 15.7% |
| 60Δ | 5.98 | 207.3% | 12.8% | 8.41 | 247.3% | 13.4% |
| 65Δ | 5.71 | 226.7% | 12.1% | 8.72 | 229.4% | 11.2% |
| 70Δ | 5.44 | 246.2% | 11.4% | 9.02 | 211.5% | 8.9% |
| 75Δ | 5.17 | 265.6% | 10.8% | 9.33 | 193.6% | 6.7% |
| 80Δ | 4.69 | 303.6% | 9.7% | 9.63 | 175.7% | 4.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.34
- IV
- 281.2%
- B/E move
- 32.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.88
- IV
- 286.1%
- B/E move
- 29.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.42
- IV
- 291.0%
- B/E move
- 26.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.96
- IV
- 295.9%
- B/E move
- 23.4%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.49
- IV
- 300.7%
- B/E move
- 20.2%
50Δ
- Pseudo strike
- 6.51
- IV
- 168.4%
- B/E move
- 14.2%
- Pseudo strike
- 7.80
- IV
- 283.1%
- B/E move
- 18.0%
55Δ
- Pseudo strike
- 6.24
- IV
- 187.9%
- B/E move
- 13.5%
- Pseudo strike
- 8.11
- IV
- 265.2%
- B/E move
- 15.7%
60Δ
- Pseudo strike
- 5.98
- IV
- 207.3%
- B/E move
- 12.8%
- Pseudo strike
- 8.41
- IV
- 247.3%
- B/E move
- 13.4%
65Δ
- Pseudo strike
- 5.71
- IV
- 226.7%
- B/E move
- 12.1%
- Pseudo strike
- 8.72
- IV
- 229.4%
- B/E move
- 11.2%
70Δ
- Pseudo strike
- 5.44
- IV
- 246.2%
- B/E move
- 11.4%
- Pseudo strike
- 9.02
- IV
- 211.5%
- B/E move
- 8.9%
75Δ
- Pseudo strike
- 5.17
- IV
- 265.6%
- B/E move
- 10.8%
- Pseudo strike
- 9.33
- IV
- 193.6%
- B/E move
- 6.7%
80Δ
- Pseudo strike
- 4.69
- IV
- 303.6%
- B/E move
- 9.7%
- Pseudo strike
- 9.63
- IV
- 175.7%
- B/E move
- 4.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 77.65% | |
| 87.65% | |
| 102.45% | |
| 104.04% | |
| 123.53% | |
| 84.77% | |
| 101.19% | |
| 97.09% | |
| 98.91% | |
| 102.93% | |
| 112.78% | |
| 97.53% |
Biotechnology
ACIU
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative…
More →ACOG
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on…
More →ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with…
More →ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and…
More →AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in…
More →AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The…
More →